Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice

H Eldar-Finkelman1, S A Schreyer, M M Shinohara

  • 1Division of Women's Health, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Diabetes
|July 30, 1999
PubMed

Insights

Increased glycogen synthase kinase-3 (GSK-3) activity in fat tissue is linked to insulin resistance and type 2 diabetes susceptibility in C57BL/6J mice, but not in resistant A/J mice.

Area of Science:

  • Metabolic diseases
  • Molecular biology
  • Endocrinology

Background:

  • Insulin resistance and type 2 diabetes mechanisms are not fully understood.
  • Defects in insulin signaling pathways are implicated.
  • Glycogen synthase kinase-3 (GSK-3) is a potential key player.

Purpose of the Study:

  • To investigate the role of GSK-3 activity in diet-induced insulin resistance.
  • To compare GSK-3 activity in obesity-susceptible (C57BL/6J) and resistant (A/J) mouse strains.

Main Methods:

  • Examined GSK-3 activity in fat, liver, and muscle tissues of mice fed high-fat vs. low-fat diets.
  • Compared GSK-3 activity between C57BL/6J and A/J mouse strains.

Main Results:

  • GSK-3 activity doubled in epididymal fat of C57BL/6J mice on a high-fat diet; unchanged in liver and muscle.
  • No change in GSK-3 activity in A/J mice fat tissue regardless of diet.
  • Basal and diet-induced GSK-3 activity was significantly higher in C57BL/6J mice adipose tissue compared to A/J mice.

Conclusions:

  • Increased GSK-3 activity in adipose tissue is linked to insulin resistance and type 2 diabetes.
  • GSK-3 may be a contributing factor to diet-induced diabetes susceptibility in C57BL/6J mice.

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...